Comparison of nested competitive RT-PCR and real-time RT-PCR for the detection and quantification of AML1/MTG8 fusion transcripts in t(8;21) positive acute myelogenous leukemia

Leukemia

Volumn 14, Issue 2, 2000, Pages 329-335

  Wattjes, M P ^b   Krauter, J ^b   Nagel, S ^b   Heidenrech, O ^b   Ganser, A ^b   Heil, G ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

^b NONE

Author keywords

AML; Competitive RT PCR; Minimal residual disease; Real time PCR

Indexed keywords

CYTARABINE;

ACUTE GRANULOCYTIC LEUKEMIA; ARTICLE; AUTOANALYSIS; CASE REPORT; CHIMERA; CHROMOSOME TRANSLOCATION 8; CONTROLLED STUDY; HUMAN; HUMAN CELL; INTERMETHOD COMPARISON; KARYOTYPE; MINIMAL RESIDUAL DISEASE; PLASMID; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

EID: 0033951322     PISSN: 08876924     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.leu.2401679     Document Type: Article

References (40)

1. Berger R, Flandrin G, Bernheim A, Le Coniat M, Vecchione D, Pacot A, Derre J, Daniel MT, Valensi F, Sigaux F, Ochoa Noguera ME. Cytogenetic studies on 519 consecutive de novo acute non-lymphocytic leukemias. Cancer Genet Cytogenet 1987; 29: 9-21.
2. Fenaux P, Preudhomme C, Lai JL, Morel P, Beuscart R, Bauters F. Cytogenetics and their prognostic value in de novo acute myeloid leukemia: a report on 283 cases. Br J Haematol 1989; 73: 61-67.
3. Erickson P, Gao J, Chang KS, Look T, Whisenant E, Raimondi S, Lasher R, Trujillo J, Rowley J, Drabkin H. Identification of breakpoints in t(8;21) acute myelogenous leukemia and isolation of a fusion transcript, AML1/ETO, with similarity to Drosophila segmentation gene, runt. Blood 1992; 80: 1825-1831.
4. Miyoshi H, Kozu T, Shimizu K, Enomoto K, Maseki N, Kaneko Y, Kamada N, Ohki M. The t(8;21) translocation in acute myeloid leukemia results in production of an AML1-MTG8 fusion transcript. EMBO J 1993; 12: 2715-2721.
5. Tighe JE, Daga A, Calabi F. Translocation breakpoints are clustered on both chromosome 8 and chromosome 21 in the t(8;21) of acute myeloid leukemia. Blood 1993; 81: 592-596.
6. Bitter MA, Le Beau MM, Rowley JD, Larson RA, Golomb HM, Vardiman JW. Associations between morphology, karyotype and clinical features in myeloid leukemias. Hum Pathol 1987; 18: 211-225.
7. Bloomfield CD, Lawrence D, Byrd JC, Carrol A, Pettenati MJ, Tantravahi R, Patil SR, Davey FR, Berg DT, Schiffer CA, Arthur DC, Mayer RJ. Frequency of prolonged remission duration after high-dose cytarabine intensification in acute myeloid leukemia varies by cytogenetic subtype. Cancer Res 1998; 58: 4173-4179.
8. Heil G, Krauter J, Raghavachar A, Hoelzer D, Hossfeld D, Mertelsmann R, Noens L, Schlimok G, Port M, Schwab G, Ganser A. Risk-adapted induction and consolidation therapy including autologous peripheral blood stem cell transplantation (PBSCT) in adult de novo AML patients. Blood 1997; 90: 508a (Abstr.).
9. Fenaux P, Lai JL, Preudhomme C, Jouet JP, Deminatti M, Bauters F. Is translocation (8;21) a 'favorable' cytogenetic rearrangement in acute myeloid leukemia? Nouv Rev Fr Hematol 1990; 32: 179-182.
10. Chang KS, Fan YH, Stass SA, Estey EH, Wang G, Trujillo JM, Erickson P, Drabkin H. Expression of AML1-ETO fusion transcripts and detection of minimal residual disease in t(8;21)-positive acute myeloid leukemia. Oncogene 1993; 8: 983-988.
11. Downing JR, Head DR, Curcio Brint AM, Hulshof MG, Motroni TA, Raimondi SC, Carroll AJ, Drabkin HA, Willman C, Theil KS, Civin Cl, Erickson P. An AML1/ETO fusion transcript is consistently detected by RNA-based polymerase chain reaction in acute myelogenous leukemia containing the (8;21)(q22;q22) translocation. Blood 1993; 81: 2860-2865.
12. Nucifora G, Larson RA, Rowley JD. Persistence of the 8;21 translocation in patients with acute myeloid leukemia type M2 in long-term remission. Blood 1993; 82: 712-715.
13. Jurlander J, Caligiuri MA, Ruutu T, Baer MR, Strout MP, Oberkircher AR, Hoffmann L, Ball ED, Frei Lahr DA, Christiansen NP, Block AM, Knuutila S, Herzig GP, Bloomfield CD. Persistence of the AML1/ETO fusion transcript in patients treated with allogeneic bone marrow transplantation for t(8;21) leukemia. Blood 1996; 88: 2183-2191.
14. Miyamoto T, Nagafuji K, Akashi K, Harada M, Kyo T, Akashi T, Takenaka K, Mizuno S, Gondo H, Okamura T, Dohy H, Niho Y. Persistence of multipotent progenitors expressing AML1/ETO transcripts in long-term remission patients with t(8;21) acute myelogenous leukemia. Blood 1996; 87: 4789-4796.
15. Elmaagacli AH, Beelen DW, Stockova J, Trzensky S, Kroll M, Schaefer UW, Stein C, Opalka B. Detection of AML1/ETO fusion transcripts in patients with t(8;21) acute myeloid leukemia after allogeneic bone marrow transplantation or peripheral blood progenitor cell transplantation. Blood 1997; 90: 3230-3231.
16. Kusec R, Laczika K, Knobl P, Friedl J, Greinix H, Kahls P, Linkesch W, Schwarzinger I, Mitterbauer G, Purtscher B, Haas O, Lechner K, Jaeger K. AML 1/ETO fusion mRNA can be detected in remission blood samples of all patients with t(8;21) acute myeloid leukemia alter chemotherapy or autologous bone marrow transplantation. Leukemia 1994; 8: 735-739.
17. Muto A, Mori S, Matsushita H, Awaya N, Ueno H, Takayama N, Okamoto S, Kizaki M, Ikeda Y. Serial quantification of minimal residual disease of t(8;21) acute myelogenous leukaemia with RT-competitive PCR assay. Br J Haematol 1996; 95: 85-94.
18. Tobal K, Yin JA. Monitoring of minimal residual disease by quantitative reverse transcriptase-polymerase chain reaction for AML 1-MTG8 transcripts in AML-M2 with t(8;21). Blood 1996; 88: 3704-3709.
19. Tobal K, Liu Yin JA. Molecular monitoring of minimal residual disease in acute myeloblastic leukemia with t(8;21) by RT-PCR. Leuk Lymphoma 1998; 31: 115-120.
20. Siebert PD, Larrick JW. Competitive PCR. Nature 1992; 359: 557-558.
21. Cross NCP, Feng L, Chase A, Bungey J, Hughes TP, Goldman JM. Competitive polymerase chain reaction to estimate the number of of bcr-abl transcripts in chronic myeloid leukemia patients after bone marrow transplantation. Blood 1993; 82: 1929-1936.
22. Meijerink JP, Smetsers TF, Raemaekers JM, Bogman MJ, De Witte T, Mensink EJ. Quantitation of follicular non-Hodgkin's lymphoma cells carrying t(14;18) by competitive polymerase chain reaction. Br J Haematol 1993; 84: 250-256.
23. Brisco MJ, Condon J, Hughes E, Neoh SH, Sykes PJ, Seshadri R, Toogood I, Waters K, Tauro G, Ekert H, Morley AA. Outcome prediction in childhood acute lymphoblastic leukaemia by molecular quantification of residual disease at the end of induction. Lancet 1994; 343: 196-200.
24. Cross NCP. Quantitative PCR techniques and applications. Br J Haematol 1995; 89: 693-697.
25. Holland PM, Abramson RD, Watson R, Gelfand DH. Detection of specific polymerase chain products by utilizing the 5′ to 3′ exonuclease activity of termus aquaticus DNA polymerase. Proc Natl Acad Sci USA 1991; 88: 7276-7280.
26. Förster VT. Zwischenmolekulare Energiewanderung und Fluoreszenz. Ann Physics (Leipzig) 1948; 2: 55-75.
27. Marcucci G, Livak KJ, Bi W, Strout MP, Bloomfield CD, Caligiuri MA. Detection of minimal residual disease in patients with AML1/ETO-associated acute myeloid leukemia using a novel quantitative reverse transcription polymerase chain reaction assay. Leukemia 1998; 12: 1482-1489.
28. Mensink E, van de Locht A, Schattenberg A, Linders E, Schaap N, Geurts van Kessel A, De Witte T. Quantitation of minimal residual disease in Philadelphia chromosome positive chronic myeloid leukemia using real-time quantitative RT-PCR. Br J Haematol 1998; 102: 768-774.
29. Luthra R, McBride JA, Cabanillas F, Sarris A. Novel 5′ exonuclease based real time PCR assay for the detection of t(14;18)(q32;q21) in patients with follicular lymphoma. Am J Pathol 1998; 153: 63-68.
30. Gerard CJ, Olsson K, Ramanathan R, Reading C, Hanania EG. Improved quantitation of minimal residual disease in multiple myeloma using real-lime polymerase chain reaction and plasmid-DNA complementarity determinig region III standards. Cancer Res 1998; 58: 3957-3964.
31. Pongers-Willemse MJ, Verhagen OJ, Tibbe GJ, Wijkhuijs AJ, de Haas V, Roovers E, van der School CE, van Dongen JJ. Real-time quantitalive PCR for the detection of minimal residual disease in acute lymphoblastic leukemia using junctional region specific TaqMan probes. Leukemia 1998; 12: 2006-2014.
32. Gibson UEM, Heid CA, Williams MP. A novel method for real time quantitative RT-PCR. Genome Res 1996; 6: 995-1001.
33. Heid CA, Stevens J, Livak KJ, Williams MP. Real time quantitative PCR. Genome Res 1996; 6: 986-994.
34. Asou H, Tashiro S, Hamamoto K, Otsuji A, Kita K, Kamada N. Establishment of a human acute myeloid leukemia cell line (Kasumi-1) with 8;21 chromosome translocation. Blood 1991; 77: 2031-2036.
35. Lanotte M, Martin-Thouvenin V, Najman S, Balerini P, Valensi F, Berger R. NB4, a maturation inducible cell line with t(15;17) marker isolated from a human acute promyelocytic leukemia (M3). Blood 1991; 77: 1080-1086.
36. Krauter J, Peter W, Pascheberg U, Heinze B, Bergmann L, Hoelzer D, Lübbert M, Schlimok G, Arnold R, Kirchner H, Port M, Ganser A, Heil G. Detection of karyotypic aberrations in acute myeloblastic leukemia: a prospective comparison between PCR/FISH and standard cytogenetics in 140 patients with de novo AML. Br J Haematol 1998; 103: 72-78.
37. Miller WH, Levine K, DeBlasio A, Frankel SR, Dmitrovsky E, Warrell RP. Detection of minimal residual disease in acute promyelocytic leukemia by a reverse transcription polymerase chain reaction assay for the PML/RAR-alpha fusion mRNA. Blood 1993; 82: 1689-1694.
38. Miyamoto T, Nagafuji K, Harada M, Eto T, Fujisaki T, Kubota A, Akashi K, Mizuno S, Takenaka K, Kanaji T et al. Quantitative analysis of AML1/ETO transcripts in peripheral blood stem cell harvests from patients with t(8;21) acute myelogenous leukaemia. Br J Haematol 1995; 91: 132-138.
39. Becker AM, Hahlbrock. K Absolute mRNA quantification using the polymerase chain reaction (PCR): a novel approach by a PCR aided transcript titration assay (PATTY). Nucleic Acids Res 1989; 17: 9437-9446.
40. Desjardin LE, Chen Y, Perkins MD, Teixeira L, Cave MD, Eisenach KD. Comparison of the ABI 7700 system (TaqMan) and competitive PCR for quantification of IS6110 DNA in sputum during treatment of tuberculosis. J Clin Microbiol 1998; 36: 1964-1968.